NK cell defects: implication in acute myeloid leukemia
Acute Myeloid Leukemia (AML) is a complex disease with rapid progression and poor/unsatisfactory outcomes. In the past few years, the focus has been on developing newer therapies for AML; however, relapse remains a significant problem. Natural Killer cells have strong anti-tumor potential against AM...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1112059/full |
| _version_ | 1797830998847651840 |
|---|---|
| author | Selma Z. D’Silva Meenakshi Singh Meenakshi Singh Andrea S. Pinto |
| author_facet | Selma Z. D’Silva Meenakshi Singh Meenakshi Singh Andrea S. Pinto |
| author_sort | Selma Z. D’Silva |
| collection | DOAJ |
| description | Acute Myeloid Leukemia (AML) is a complex disease with rapid progression and poor/unsatisfactory outcomes. In the past few years, the focus has been on developing newer therapies for AML; however, relapse remains a significant problem. Natural Killer cells have strong anti-tumor potential against AML. This NK-mediated cytotoxicity is often restricted by cellular defects caused by disease-associated mechanisms, which can lead to disease progression. A stark feature of AML is the low/no expression of the cognate HLA ligands for the activating KIR receptors, due to which these tumor cells evade NK-mediated lysis. Recently, different Natural Killer cell therapies have been implicated in treating AML, such as the adoptive NK cell transfer, Chimeric antigen receptor-modified NK (CAR-NK) cell therapy, antibodies, cytokine, and drug treatment. However, the data available is scarce, and the outcomes vary between different transplant settings and different types of leukemia. Moreover, remission achieved by some of these therapies is only for a short time. In this mini-review, we will discuss the role of NK cell defects in AML progression, particularly the expression of different cell surface markers, the available NK cell therapies, and the results from various preclinical and clinical trials. |
| first_indexed | 2024-04-09T13:45:06Z |
| format | Article |
| id | doaj.art-eb7b2c191d1b46598cb350753341cfdf |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T13:45:06Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-eb7b2c191d1b46598cb350753341cfdf2023-05-09T05:26:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.11120591112059NK cell defects: implication in acute myeloid leukemiaSelma Z. D’Silva0Meenakshi Singh1Meenakshi Singh2Andrea S. Pinto3Transplant Immunology and Immunogenetics Lab, Advanced Centre for Treatment, Education and Research in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, IndiaTransplant Immunology and Immunogenetics Lab, Advanced Centre for Treatment, Education and Research in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, IndiaHomi Bhabha National Institute, Mumbai, IndiaTransplant Immunology and Immunogenetics Lab, Advanced Centre for Treatment, Education and Research in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, IndiaAcute Myeloid Leukemia (AML) is a complex disease with rapid progression and poor/unsatisfactory outcomes. In the past few years, the focus has been on developing newer therapies for AML; however, relapse remains a significant problem. Natural Killer cells have strong anti-tumor potential against AML. This NK-mediated cytotoxicity is often restricted by cellular defects caused by disease-associated mechanisms, which can lead to disease progression. A stark feature of AML is the low/no expression of the cognate HLA ligands for the activating KIR receptors, due to which these tumor cells evade NK-mediated lysis. Recently, different Natural Killer cell therapies have been implicated in treating AML, such as the adoptive NK cell transfer, Chimeric antigen receptor-modified NK (CAR-NK) cell therapy, antibodies, cytokine, and drug treatment. However, the data available is scarce, and the outcomes vary between different transplant settings and different types of leukemia. Moreover, remission achieved by some of these therapies is only for a short time. In this mini-review, we will discuss the role of NK cell defects in AML progression, particularly the expression of different cell surface markers, the available NK cell therapies, and the results from various preclinical and clinical trials.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1112059/fullnatural killer cellsimmunotherapyAMLCAR-NKBiKEsTriKEs |
| spellingShingle | Selma Z. D’Silva Meenakshi Singh Meenakshi Singh Andrea S. Pinto NK cell defects: implication in acute myeloid leukemia Frontiers in Immunology natural killer cells immunotherapy AML CAR-NK BiKEs TriKEs |
| title | NK cell defects: implication in acute myeloid leukemia |
| title_full | NK cell defects: implication in acute myeloid leukemia |
| title_fullStr | NK cell defects: implication in acute myeloid leukemia |
| title_full_unstemmed | NK cell defects: implication in acute myeloid leukemia |
| title_short | NK cell defects: implication in acute myeloid leukemia |
| title_sort | nk cell defects implication in acute myeloid leukemia |
| topic | natural killer cells immunotherapy AML CAR-NK BiKEs TriKEs |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1112059/full |
| work_keys_str_mv | AT selmazdsilva nkcelldefectsimplicationinacutemyeloidleukemia AT meenakshisingh nkcelldefectsimplicationinacutemyeloidleukemia AT meenakshisingh nkcelldefectsimplicationinacutemyeloidleukemia AT andreaspinto nkcelldefectsimplicationinacutemyeloidleukemia |